XOLAIR is FDA-approved for use in appropriate patients with Allergic Asthma and also appropriate patients with CIU. Dosing varies by indication, so be sure to follow the correct dosing and frequency instructions for your patient’s condition.

Administer XOLAIR only in a healthcare setting by healthcare providers prepared to manage anaphylaxis that can be life-threatening. Be sure to provide and instruct patients to read the XOLAIR Medication Guide before starting treatment and before each subsequent treatment.

Dosing for Allergic Asthma

XOLAIR is administered every 2 or 4 weeks. The patient's age, pretreatment serum total immunoglobulin E (IgE) level (IU/mL), and body weight (lb or kg) are used to determine doses (mg) and dosing frequency. Periodically reassess the need for continued therapy based on the patient’s disease severity and level of asthma control. 1

Dosing for CIU

XOLAIR is administered every 4 weeks. Dosing of XOLAIR in CIU patients is flat-fixed and NOT dependent on serum IgE (free or total) level or body weight. The appropriate duration of therapy has not been evaluated. Periodically reassess the need for continued therapy. 1

How to Prepare & Administer XOLAIR

XOLAIR is administered subcutaneously every 2 or 4 weeks for Allergic Asthma and every 4 weeks for CIU. 1 Observe patients closely for an appropriate period after administration, considering the time to onset of anaphylaxis seen in premarketing clinical trials and postmarketing spontaneous reports. See additional Important Safety Information about anaphylaxis.

XOLAIR CO-PAY CARD

XOLAIR Co-pay Card Icon

Help eligible patients with out-of-pocket costs through the XOLAIR Co-pay Card Program.

PATIENT RESOURCES

Download XOLAIR Resources Icon

Download and share support resources, such as the Patient Treatment Guides, with your Allergic Asthma and CIU patients when discussing XOLAIR.